PR Newswire Clinical TrialsOriginal article
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer
Phase 1positiveRC220osimertinibPositive
AI Analysis
Summary
Racura Oncology's Safety Review Committee cleared RC220 to escalate to 100 mg/m2 in the Phase 1 HARNESS-1 trial after observing no dose-limiting toxicities or safety concerns in Cohort 1 patients receiving the drug in combination with osimertinib for EGFR-mutant non-small cell lung cancer.
Clinical Trial Data
Phase
Phase 1
Patients
2
Outcome Details
RC220 dose escalated to 100 mg/m2; no dose-limiting toxicities or treatment-related safety concerns identified in Cohort 1
Importance:5/10
Sentiment:
0.70
oncologylung cancerEGFR-mutantdose escalationsafety
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 12, 2026 11:00 AM